Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)

BACKGROUND: Infliximab (INX) and other tumour necrosis factor inhibitors (TNFi) have revolutionised the treatment of several immune mediated inflammatory diseases. Still, many patients do not respond sufficiently to therapy or lose efficacy over time. The large interindividual variation in serum dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Syversen, Silje W, Goll, Guro L, Jørgensen, Kristin K, Olsen, Inge C, Sandanger, Øystein, Gehin, Johanna E, Warren, David J, Sexton, Joseph, Mørk, Cato, Jahnsen, Jørgen, Kvien, Tore K, Bolstad, Nils, Haavardsholm, Espen A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945422/
https://www.ncbi.nlm.nih.gov/pubmed/31907007
http://dx.doi.org/10.1186/s13063-019-3734-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945422/
https://www.ncbi.nlm.nih.gov/pubmed/31907007
http://dx.doi.org/10.1186/s13063-019-3734-4

Ejemplares similares